Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study
2023; Lippincott Williams & Wilkins; Volume: 119; Issue: 5 Linguagem: Inglês
10.14309/ajg.0000000000002621
ISSN1572-0241
AutoresWaqqas Afif, Ramesh Arasaradnam, María T. Abreu, Silvio Danese, William J. Sandborn, Ye Miao, Hongyan Zhang, Remo Panaccione, Tadakazu Hisamatsu, Ellen Scherl, Rupert W. Leong, David Rowbotham, Laurent Peyrin‐Biroulet, Bruce E. Sands, Colleen Marano,
Tópico(s)Diagnosis and treatment of tuberculosis
ResumoUlcerative colitis (UC) is a chronic condition that may require long-term treatment. We report the final efficacy and safety results of the UNIFI long-term extension study of ustekinumab in patients with UC through 4 years.
Referência(s)